HOME >> BIOLOGY >> NEWS
Clinical trial to test stem cell approach for children with brain injury

HOUSTON -- (Dec. 20, 2005) A unique clinical trial will gauge the safety and potential of treating children suffering traumatic brain injury with stem cells derived from their own bone marrow starting early next year at The University of Texas Medical School at Houston and Memorial Hermann Children's Hospital.

The clinical trial is the first to apply stem cells to treat traumatic brain injury. It does not involve embryonic stem cells.

"There is no reparative treatment for traumatic brain injury," said principal investigator Charles Cox, M.D., The Children's Fund, Inc. Distinguished Professor in Pediatric Surgery and Trauma at the medical school. "All we can do now is try to prevent secondary damage by relieving pressure on the brain caused by the initial injury."

Unlike bone, muscle and other organs, the brain does not repair itself effectively. Traumatic brain injury victims can regain some function through rehabilitation. Studies show between 15 and 25 percent of children suffering severe traumatic brain injury die, and survivors of even moderate injury often are devastated for life.

Approved by the U.S. Food and Drug Administration and the university's Committee for the Protection of Human Subjects (CPHS), the clinical trial builds on laboratory and animal research indicating that bone-marrow derived stem cells can migrate to an injured area of the brain, differentiate into new neurons and support cells, and induce brain repair.

"This would be an absolutely novel treatment, the first ever with potential to repair a traumatically damaged brain," said James Baumgartner, M.D., associate professor of pediatric neurosurgery and co-principal investigator on the project.

As a Phase I clinical trial, the project's first emphasis is to establish the safety of the procedure, with a secondary goal of observing possible therapeutic effects.

Cox and Baumgartner have permission to recruit 10 head injury p
'"/>

Contact: Scott Merville
scott.merville@uth.tmc.edu
713-500-3042
University of Texas Health Science Center at Houston
20-Dec-2005


Page: 1 2 3

Related biology news :

1. 2007-2008 Genzyme/ACMGF Clinical Genetics Fellowship In Biochemical Genetics award winner announced
2. Scientists honored with Excellence in Clinical Research Award
3. Clinical trial data regarding NKTR-061 will be presented at ATS International Conference
4. Clinical trial for diabetic macular edema
5. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
6. Research and program highlights of the 2007 Annual Clinical Genetics Meeting, March 21-25, 2007
7. American College of Medical Genetics -- 2007 Annual Clinical Genetics Meeting Announcement
8. October MCP: A special issue on Clinical Proteomics
9. Columbia University Medical Center receives major new NIH Clinical Science investment funds
10. Researchers reverse juvenile diabetes in animal model; Clinical trial FDA approved
11. Vaccine trials inject hope into koalas future

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Clinical trial test stem cell approach for children with brain injury

(Date:8/22/2014)... the birds and the bees. But that old ... fertilized. The fertilization process for flowering plants is ... male and female reproductive cells. New research from ... Munich, and including Carnegie,s Wolf Frommer, David Ehrhardt, ... signaling process that guides flowering plant fertilization. It ...
(Date:8/21/2014)... -- Nxt-ID, Inc. (OTCQB: NXTD), a biometric authentication company ... that its shares of common stock and the warrants ... proposed underwritten public offering of common stock and warrants ... Market, subject to closing of its proposed underwritten public ... trade under the symbol "NXTD" and "NXTDW," respectively. ...
(Date:8/21/2014)... Aug. 21, 2014 /PRNewswire-iReach/ -- LiveScan Service ... agreed to a partnership with Gabriel Health Institute, ... fastest growing Certified Nursing Assistant preparatory schools. ...  an exclusive member of Binary,s LiveScan service provider,s ... will improve its service capabilities by widening ...
Breaking Biology News(10 mins):Calcium and reproduction go together 2Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3
(Date:8/21/2014)...  BioSpecifics Technologies Corp. (NASDAQ: BSTC ... collagenase-based products marketed as XIAFLEX ® (collagenase ... XIAPEX ® in the EU, today announced ... Phase 2a study of CCH for the potential ... results showed that all three doses of CCH ...
(Date:8/21/2014)... DUBLIN, Ireland , August 21, 2014 ... and Markets ( http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the ... Market 2014-2018"  report to their offering.  ... also known as hormone therapy, is a ... longer being produced by the body. This ...
(Date:8/21/2014)... NEW YORK , Aug. 21, 2014 Mathematic ... at Harvard University , and funded by the ... aggressive cells within tumors can be visually identified for elimination. ... tumor,s growth. The study, which shows a topological map of ... needed time in cancer research, for while tumor cells can ...
(Date:8/21/2014)... Ontotext S4 , The Self ... . Now the same enterprise hardened text mining, ... unstructured data is available to start-ups and mid-size businesses ... Organizations that do not have resources to evaluate and ... S4 since there is no need for on premise ...
Breaking Biology Technology:BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4
Cached News: